Introduction: At the present time, inhibitors of phosphodiesterase type 5 (PDE5) have Food
and Drug Administration approval only for the treatment of erectile dysfunction and …

The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly
owing to underlying endothelial dysfunction in both diseases. Millions of patients with …

ABSTRACT Introduction Phosphodiesterase 9 (PDE9) has been demonstrated as a
potential target for neurological disorders and cardiovascular diseases, such as Alzheimer's …

Introduction-The cyclic nucleotides cAMP and cGMP are principal components of cell signal
transduction pathways. Intracellular degradation of these key second messengers is carried …

ABSTRACT Introduction Phosphodiesterase type 5 (PDE5) inhibitors are widely used as first-
line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an …

PDE-5 inhibitors were originally studied in cardiovascular indications but were later
developed and approved for on-demand treatment of erectile dysfunction (ED). A few years …

Introduction Cyclic nucleotide phosphodiesterase 4 (PDE4) is responsible for the hydrolysis
of cAMP, which has become an attractive therapeutic target for lung, skin, and severe …

Phosphodiesterase type 5 (PDE5) is one member of a superfamily of cyclic nucleotide
hydrolyzing enzymes that specifically cleaves cyclic guanosine monophosphate (cGMP), a …

Phosphodiesterase type-5 (PDE5) inhibitors are widely used as first-line therapy for erectile
dysfunction (ED). Their efficacy and safety combined with an increasing understanding of …

Of the current options available to treat erectile dysfunction, oral phosphodiesterase type 5
(PDE5) inhibitors are the recommended first‐line treatment. This review compares the three …